数据显示，中国干细胞临床研究项目数量已位居全球第二，适应症集中于呼吸系统疾病、神经系统疾病 等高发领域，临床转化进入加速兑现期。博雅干细胞以质量体系为基石，深度联动多家三甲医院推进产 学研医融合，将标准化存储的胎盘、脐带干细胞与临床研究需求精准对接，在骨关节损伤、神经退行性 等领域探索技术应用价值。同时，凭借全链条专利布局与智能化生产技术，积极拓展外泌体等新兴赛 道，推动干细胞技术从疾病治疗向健康养护延伸，契合人口老龄化背景下的全民健康需求升级。 行业向高质量发展转型的过程中，全链条高标准不仅是企业突围的关键，更是赋能产业升级、惠及民生 健康的核心支撑。博雅干细胞作为第一梯队代表，以超过 15 万家庭的服务积累，印证了高质量体系对 品牌公信力的塑造作用。未来，在监管持续深化与技术迭代加速的趋势下，质量将持续主导干细胞行业 格局。博雅干细胞将继续以全链高标准为核心，深耕技术创新与临床转化，在引领行业规范化发展的同 时，让高质量干细胞技术更广泛地服务于民生健康，为健康中国战略落地注入强劲动能，彰显头部企业 的责任与担当。 随着 "药品" 与 "医疗技术" 双轨并行备案制的持续完善，建立符合药品 GMP 规范的全流 ...

新华社北京1月22日电 加拿大不列颠哥伦比亚大学日前宣布，该校研究人员开发出一项新技术，可利 用干细胞批量生产一类重要免疫细胞——辅助性T细胞，有望大幅降低用细胞疗法治疗癌症等疾病的成 本，并简化其流程。 相关论文发表在美国学术期刊《细胞-干细胞》上。（完） 细胞疗法指利用活细胞来治疗疾病的方法，例如治疗癌症的CAR-T细胞疗法就是基因改造T细胞，使其 能精准识别和攻击癌细胞。由于需要提取患者自身的T细胞来培养，流程复杂、耗时较长且成本高昂， 这种疗法难以普及。 研究人员尝试抑制该信号通路，精准调控发育过程中的刺激信号强度，成功使干细胞发育成为成熟的辅 助性T细胞，后者在外观和功能上都与人体本身的辅助性T细胞非常相似。 辅助性T细胞能调动和增强其他免疫细胞的功能，就像战场上的指挥官，只有在它们的协调下，细胞毒 性T细胞才能充分发挥杀灭癌细胞的作用。这项新成果意味着将来可以经济、高效地生产这两类T细胞 的组合，大幅增强细胞疗法的有效性和灵活性。 人类多能干细胞能无限增殖，且易于被基因改造。医学界已经成功使其分化为直接杀伤癌细胞的细胞毒 性T细胞，但还无法有效培养出成熟的辅助性T细胞。 不列颠哥伦比亚大学的研究人 ...

Group 1 - The core point of the article is that Jiangxi Jindalai Environmental Protection Co., Ltd. plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake, driven by optimism about the development prospects of stem cell technology and its applications [1][3] - Jindalai aims to optimize its industrial structure and seek new growth opportunities to enhance its risk resistance and cultivate new profit growth points through investments in strategic emerging industries like biomanufacturing and health care [3][4] Group 2 - Jindalai is recognized as an advanced innovative comprehensive service provider for water environment governance, with its main products and services including water pollution control equipment and overall solutions for water environment [2] - The company's FMBR wastewater treatment system is characterized by simplicity, originality, and modernization, offering significant advantages over traditional wastewater treatment methods, such as reduced sludge volume and lower comprehensive costs [2] - Jici Medical specializes in the research and application of autologous cell technology, holding unique advantages in the field of cell reprogramming and rejuvenation, with a series of patented technologies for developing various functional cells [4][6] Group 3 - Jici Medical has developed an autologous rFib injection that has been tested for safety and efficacy across over 30 clinical indications, with plans to enter the pre-IND stage for some products [5][6] - The company has established multiple research platforms in collaboration with various institutions to promote technology transfer and high-end talent cultivation [5][6] - As of September 30, 2025, Jici Medical reported total assets of 10.01 million yuan, with revenues and net profits of 11.23 million yuan and 1.15 million yuan respectively, indicating a modest performance due to limited funding and small operational scale [6]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 金达莱(688057.SH)公告称，公司基于对干细胞技术的研发与应用等国家战略性新兴行业发展前景看 好，拟逐步优化公司产业结构，为未来发展寻找新的产业机会，以提高公司的抗风险能力，培育新的利 润增长点。公司拟以2.8亿元向云南济慈医疗科技有限公司（简称"济慈医疗"）增资。交易完成后，公 司将持有济慈医疗34%的股权。标的公司及其子公司的主营业务为自体细胞技术的研发与应用。 ...

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Yunnan Jici Medical Technology Co., Ltd. [1] Group 1 - The company intends to invest 280 million yuan of its own funds to acquire a 34% stake in Yunnan Jici Medical Technology Co., Ltd. [1] - Yunnan Jici Medical has unique advantages in the field of cell dedifferentiation and rejuvenation research, having established a technology system that induces skin fibroblasts into specific functional cells without going through the induced pluripotent stem cell (iPSC) stage [1] - The company has developed a series of autologous cell preparations or their derivatives, including first-generation induced mesenchymal stem cells (rFib), second-generation induced mesenchymal stem cells (cFib), induced osteoblasts (iOB), induced chondrocytes (iCH), induced neurons (iNC), induced endothelial cells (iEC), and induced vascular smooth muscle cells (iVSMC) [1] Group 2 - Yunnan Jici Medical has pioneered a new field of autologous cell therapy and tissue engineering for refractory diseases, particularly refractory geriatric diseases, based on its original series of stem cell patent technologies [2] - The company has obtained 20 invention patents in countries including China, the United States, Japan, Canada, Australia, and Malaysia [2]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Yunnan Jici Medical Technology Co., Ltd. [1] Group 1 - The company intends to invest 280 million yuan of its own funds to acquire a 34% stake in Yunnan Jici Medical Technology Co., Ltd. [1] - Yunnan Jici Medical has unique advantages in the field of cell dedifferentiation and rejuvenation research, having established a technology system that induces skin fibroblasts into specific functional cells without going through the induced pluripotent stem cell (iPSC) stage [1] - The company has developed a series of autologous cell preparations or their derivatives, including first-generation induced mesenchymal stem cells (rFib), second-generation induced mesenchymal stem cells (cFib), induced osteoblasts (iOB), induced chondrocytes (iCH), induced neurons (iNC), induced endothelial cells (iEC), and induced vascular smooth muscle cells (iVSMC) [1] Group 2 - Yunnan Jici Medical has pioneered a new field of autologous cell therapy and tissue engineering research for refractory diseases, particularly refractory geriatric diseases, based on its original series of stem cell patent technologies [2] - The company has obtained 20 invention patents in countries including China, the United States, Japan, Canada, Australia, and Malaysia [2]

金达莱(688057)12月19日公告，公司基于对干细胞技术的研发与应用等国家战略性新兴行业发展前景看 好，拟逐步优化公司产业结构，为未来发展寻找新的产业机会，以提高公司的抗风险能力，培育新的利 润增长点。公司拟以2.8亿元向云南济慈医疗科技有限公司（简称"济慈医疗"）增资。交易完成后，公 司将持有济慈医疗34%的股权。标的公司及其子公司的主营业务为自体细胞技术的研发与应用。 ...

Core Insights - The Shenzhen Innovation Drug Development Forum showcased ten innovative drug results, highlighting Shenzhen's strength in biopharmaceutical innovation and the integration of AI in drug development [3][4]. Group 1: Innovative Drug Results - AS1501, developed by Shenzhen University of Technology and a local pharmaceutical company, is the world's first TRAIL-DR5 pathway blocker for severe liver conditions, currently in clinical phase II, with no direct global competitors [3][4]. - BrAD-R13, a small molecule drug targeting Alzheimer's disease, has completed clinical phase I and is moving towards product transformation, aiming to provide effective treatment options for millions of patients [4]. - The AI-driven autonomous experimental platform by Crystal Technology has signed a collaboration order worth $59.9 billion with overseas pharmaceutical companies, marking a significant achievement in AI drug development [5]. Group 2: Collaborations and Innovations - A collaboration agreement worth $16.4 billion was established between Pruijng and Kite for the development of the first CAR-T therapy pipeline authorized for external use, indicating a new phase in China's in-situ editing therapy [5]. - Xinlitai launched a national class 1 innovative drug, Xiliting, for type 2 diabetes treatment, characterized by rapid oral absorption and high selectivity [5]. - Leiman Bio developed a low-dose cell therapy that can achieve 100% complete remission for advanced hematological tumors and systemic lupus erythematosus, significantly reducing production costs and treatment cycles [5].

Core Insights - The fourth "Jingcai Dachuang" Beijing University Student Innovation and Entrepreneurship Competition concluded with Beijing Forestry University's project on "Global Fault Leading Embodied Intelligent Specialized 42-Degree of Freedom Flexible Dexterous Hand Technology and Applications" winning the championship [1] - The competition attracted a record 8,468 entrepreneurial teams since its launch in March, establishing itself as a comprehensive innovation and entrepreneurship ecosystem platform [1] Group 1: Competition Highlights - Six elite teams showcased "hard technology" projects, including dexterous robotic hands, low-orbit satellite systems, and cross-species tumor gene therapy [2] - The champion team developed a dexterous hand that mimics human finger flexibility and durability, integrating a self-developed operating system and AI content generation system for full-chain automation [2] - Beijing University's "Greenvirosynergy" team created a novel gene therapy targeting prostate and bladder cancers, enhancing viral vector efficiency and targeting capabilities [2] Group 2: Investment Alliance Formation - The "Jingcai Dachuang Investment Alliance" was established to create a professional and ecological capital connection platform, facilitating the transformation of university scientific achievements [4] - The alliance aims to integrate market insights and investment logic into the selection process, providing a "financing express" and resource connection for excellent projects [4] - The initiative seeks to enhance the service chain for technology innovation results, promoting a two-way approach between university innovation resources and market demands [4] Group 3: Future Directions - The "Jingcai Dachuang" initiative will continue to deepen collaborative innovation practices among government, industry, academia, and research, focusing on event-driven support and ecosystem empowerment [5] - The goal is to enable more aspiring youth to shine on the broad stage of high-quality development in the capital [5]

Core Viewpoint - The company is strategically investing in stem cell technology through equity stakes in two firms, focusing on innovation and future application potential [2] Group 1: Investment Strategy - The company has invested in Zhejiang Shengchuang Precision Medical Technology Co., Ltd. and Shanghai Aisaar Biotechnology Co., Ltd., both related to stem cell technology [2] - The investment decision will consider factors such as product innovation, technological advancement, and future application prospects [2] - The company emphasizes a cautious approach in selecting investment projects based on its development needs [2]